Searching Relevant Polymorphisms of CYP2B6 in HIV Infected Patients

Tomaz R.1, Fernandes A.1,2, Cruz JP.2,3, Martins, R.1, Morais JG.3, Ribeiro AC.1
1. Laboratório de Biologia Molecular, ISCSEM – Centro de Investigação interdisciplinar Egas Moniz, Almada, Portugal.
2. Laboratório de Diagnóstico Molecular de Doenças Infecciosas, Faculdade de Medicina da Universidade de Lisboa, Portugal.

Review

The CYP2B6 belongs to the family of Cytochrome P450 enzymes that catalyze the metabolism of a wide variety of drugs, including the anti-retroviral EFV. The CYP2B6 gene, that has been mapped in the chromosome 19, is highly polymorphic and some SNP, namely 516G>T and 785A>G, are associated with decreased protein expression. These variants are related to phenotypes that are characterized as EFV poor metabolizers, and consequently to episodes of neurotoxicity.

Identification and characterization of the major CYP2B6 polymorphisms in 48 HIV patients receiving antiretroviral therapy with EFV.

Materials and Methods

Objective

Identification and characterization of the major CYP2B6 polymorphisms in 48 HIV patients receiving antiretroviral therapy with EFV.

Results

All the samples were classified as having the 785AG genotype.

Of all the 48 patients, 21 had the 516GG genotype and 27 has the 516GT genotype. None of the SNP were in Hardy-Weinberg equilibrium which may mean that the gene is evolving.

The genotype frequencies for the SNP 516G>T are the same among males and females (p-value > 0.05), table 2. The comparison of frequencies for the 516G>T by races also doesn’t show statistical significance, table 3.

Taking account to the results obtained, 27 subjects were classified as being intermediate metabolizers and 21 as being poor or intermediate metabolizers.

Population Characteristics

The sample was composed by 48 individuals infected with HIV-1 receiving ARV therapy with EFV. In terms of gender, 39 were male and 9 were female. Relatively to the race 39 were Caucasian and 9 African.

Conclusion

The study of the CYP2B6 gene variants is essential to provide information to complete the evaluation of the impact of these polymorphisms in ARV.

There were no differences observed in the allelic and genotyping frequencies between genders and races.

Of the 48 patients, 27 were classified as having the CYP2B6 *1/*4 haplotype (intermediate metabolizers) and 21 as having CYP2B6 *1/*6 or *6/*6 haplotype (intermediate or poor metabolizers).

References


Acknowledgements

This work was supported with Project INTELEGENDTDC/DTP-FTQ/1747/2012 from Fundação para a Ciência e Tecnologia, Lisboa, Portugal.